公司资料
Alnylam Pharmaceuticals, Inc. 股价、新闻与催化剂
- 股票代码:
- ALNY
- 交易所:
- NASDAQ
- 行业:
- Nucleic Acid Drugs
- 所在地:
- Cambridge, Massachusetts
股票表现
224.60 USD (-1.77%)
收盘价
最后更新: 2026年8月17日
38.2B USD
市值
股价为何变动
As of Aug 17, 2026, ALNY closed down 1.77% at $224.60. No new same-company headline was identified in the current news window.
公司概览
业务概览
Alnylam Pharmaceuticals is the pioneer of RNA interference therapeutics and one of the most important platform biotech companies in the market. Its approved medicines and pipeline programs focus on rare diseases and increasingly on more prevalent conditions.
所在地与行业分类
Headquartered in Cambridge, Massachusetts and listed on NASDAQ, Alnylam is a U.S.-based biotech with a growing global commercial footprint. It sits squarely in the innovation-heavy side of biotechnology.
商业模式特征
The company combines product revenue, launch execution, and platform expansion with a deep RNAi pipeline. Investors watch adoption of approved medicines, label expansions, manufacturing scale, and the next wave of RNAi programs.
生物医药行业定位
Alnylam occupies a top-tier position in platform biotech because it has already proved RNAi can work commercially. Compared with earlier-stage names, it has more durability, but it still reacts to regulatory and pipeline milestones.
未来催化剂
- Alnylam’s near-term catalysts are Amvuttra growth in ATTR-CM, Zilebesiran development, and broader RNAi adoption in cardiometabolic and rare disease. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。